首页> 外文OA文献 >Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine
【2h】

Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine

机译:布托啡诺鼻喷雾剂与西咪替丁之间缺乏药代动力学相互作用

摘要

The potential for a pharmacokinetic interaction between butorphanol nasal spray and cimetidine, under steady state conditions, was evaluated in 16 healthy male volunteers. Subjects received either a 1 mg butorphanol nasal spray every 6 h or a 300 mg cimetidine tablet every 6 h on days 1–4, the combination of two compounds every 6 h on days 5–8 and the original treatment as described in the first segment (days 1–4) on days 9–12. Serial blood and urine samples were collected on days 4, 8 and 12, and additional blood samples were taken immediately, prior to the morning dose on days 3, 7 and 11. Based on the analysis of the Cmin samples, the plasma concentrations of cimetidine and butorphanol achieved steady state by the third day of dosing. No statistically significant differences were found in the plasma concentrations of butorphanol or cimetidine (except for t½ and MRT) between any of the treatment phases. Butorphanol nasal spray and cimetidine can be co-administered without any adjustment of dosage for either drug.
机译:在16位健康的男性志愿者中,评估了稳态条件下布托啡诺鼻喷雾剂和西咪替丁之间药代动力学相互作用的可能性。在第1-4天,受试者每6h服用1μmg的布托啡诺鼻喷雾剂,或每6h服用300μmg的西咪替丁片剂,在5-8天每6h服用两种化合物的组合,以及最初的治疗方法(第1-4天)(第9-12天)。在第4、8和12天收集连续的血液和尿液样本,并在第3、7和11天的早晨剂量之前立即采血。根据Cmin样品的分析,西咪替丁的血浆浓度服药第3天,布托啡诺达到稳态。在任何治疗阶段之间,布托啡诺或西咪替丁的血浆浓度(t1 / 2和MRT除外)均未发现统计学上的显着差异。可以将布托啡诺鼻喷雾剂和西咪替丁同时使用,而无需调整任何一种药物的剂量。

著录项

  • 作者

    SHYU W. C.; BARBHAIYA R. H.;

  • 作者单位
  • 年度 100
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号